Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial J Grebely, O Dalgard, B Conway, EB Cunningham, P Bruggmann, ... The lancet Gastroenterology & hepatology 3 (3), 153-161, 2018 | 304 | 2018 |
Challenges in maintaining treatment services for people who use drugs during the COVID-19 pandemic A Dunlop, B Lokuge, D Masters, M Sequeira, P Saul, G Dunlop, J Ryan, ... Harm reduction journal 17 (1), 26, 2020 | 301 | 2020 |
Nabiximols as an agonist replacement therapy during cannabis withdrawal: a randomized clinical trial IS Allsop, David J., Copeland, Jan, Lintzeris, Nicholas, Dunlop, Adrian J ... JAMA Psychiatry 71 (3), 281-291, 2014 | 289 | 2014 |
Addiction stigma and the biopolitics of liberal modernity: A qualitative analysis S Fraser, K Pienaar, E Dilkes-Frayne, D Moore, R Kokanovic, C Treloar, ... International Journal of Drug Policy 44, 192-201, 2017 | 190 | 2017 |
Assessment and treatment of hepatitis C virus infection among people who inject drugs in the opioid substitution setting: ETHOS study M Alavi, J Grebely, M Micallef, AJ Dunlop, AC Balcomb, CA Day, ... Clinical Infectious Diseases 57 (suppl_2), S62-S69, 2013 | 137 | 2013 |
LAAM maintenance vs methadone maintenance for heroin dependence NC Clark, N Lintzeris, A Gijsbers, G Whelan, A Dunlop, A Ritter, WW Ling, ... Cochrane Database of Systematic Reviews 2010 (1), 1996 | 126 | 1996 |
National guidelines for medication-assisted treatment of opioid dependence L Gowing, R Ali, A Dunlop, M Farrell, N Lintzeris Canberra: Commonwealth of Australia, 38-9, 2014 | 117 | 2014 |
Concurrent buprenorphine and benzodiazepines use and self‐reported opioid toxicity in opioid substitution treatment S Nielsen, P Dietze, N Lee, A Dunlop, D Taylor Addiction 102 (4), 616-622, 2007 | 111 | 2007 |
A randomized trial of effectiveness and cost‐effectiveness of observed versus unobserved administration of buprenorphine–naloxone for heroin dependence J Bell, M Shanahan, C Mutch, F Rea, A Ryan, R Batey, A Dunlop, ... Addiction 102 (12), 1899-1907, 2007 | 108 | 2007 |
Long‐term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out‐patients with opioid use disorder M Frost, GL Bailey, N Lintzeris, J Strang, A Dunlop, EV Nunes, JB Jansen, ... Addiction 114 (8), 1416-1426, 2019 | 97 | 2019 |
Validation and implementation of the A ustralian Treatment Outcomes Profile in specialist drug and alcohol settings A Ryan, J Holmes, V Hunt, A Dunlop, K Mammen, R Holland, Y Sutton, ... Drug and Alcohol Review 33 (1), 33-42, 2014 | 92 | 2014 |
Nabiximols for the treatment of cannabis dependence: a randomized clinical trial N Lintzeris, A Bhardwaj, L Mills, A Dunlop, J Copeland, I McGregor, ... JAMA internal medicine 179 (9), 1242-1253, 2019 | 90 | 2019 |
Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: the SIMPLIFY study EB Cunningham, J Amin, JJ Feld, J Bruneau, O Dalgard, J Powis, ... International journal of drug policy 62, 14-23, 2018 | 83 | 2018 |
National clinical guidelines and procedures for the use of buprenorphine in the treatment of opioid dependence N Lintzeris, N Clark, A Winstock, A Dunlop, P Muhleisen, L Gowing, R Ali, ... Canberra: Commonwealth of Australia, 2006 | 82 | 2006 |
Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study J Grebely, M Alavi, M Micallef, AJ Dunlop, AC Balcomb, N Phung, ... Addiction 111 (2), 311-319, 2016 | 80 | 2016 |
Reorganization of substance use treatment and harm reduction services during the COVID-19 pandemic: a global survey SR Radfar, CAJ De Jong, A Farhoudian, M Ebrahimi, P Rafei, M Vahidi, ... Frontiers in Psychiatry 12, 639393, 2021 | 79 | 2021 |
Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: a modelling study JA Kwon, GJ Dore, J Grebely, B Hajarizadeh, R Guy, EB Cunningham, ... Journal of viral hepatitis 26 (1), 83-92, 2019 | 75 | 2019 |
A global survey on changes in the supply, price, and use of illicit drugs and alcohol, and related complications during the 2020 COVID-19 pandemic A Farhoudian, SR Radfar, H Mohaddes Ardabili, P Rafei, M Ebrahimi, ... Frontiers in psychiatry 12, 646206, 2021 | 71 | 2021 |
Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study AD Marshall, M Micallef, A Erratt, J Telenta, C Treloar, H Everingham, ... International Journal of Drug Policy 26 (10), 984-991, 2015 | 71 | 2015 |
Patient-reported outcomes of treatment of opioid dependence with weekly and monthly subcutaneous depot vs daily sublingual buprenorphine: a randomized clinical trial N Lintzeris, AJ Dunlop, PS Haber, DI Lubman, R Graham, S Hutchinson, ... JAMA Network Open 4 (5), e219041-e219041, 2021 | 68 | 2021 |